Stocks of Qiagen N.V. (NYSE:QGEN) traded higher last session on Wall Street, down -0.67% to $50.22.
According to the data, Qiagen N.V. (NYSE:QGEN) has 20 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $62.00 and a low of $42.50, we find $54.50. Given the previous closing price of $50.56, this indicates a potential upside of 7.79 percent. QGEN stock price is now 3.47% away from the 50-day moving average and 7.82% away from the 200-day moving average. The market capitalization of the company currently stands at $11.46B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 12 analysts have issued a hold rating and 8 have given it a buy rating. Brokers who have rated the stock have averaged $53.32 as their price target over the next twelve months.
, while ‘Cowen’ rates the stock as ‘Market Perform’.
Insiders disposed of 153,039 shares of company stock worth roughly $7.69 million over the past 1 year. A total of 3.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in QGEN stock. A new stake in Qiagen N.V. shares was purchased by ALYESKA INVESTMENT GROUP, L.P. during the first quarter worth $15,066,000. JANE STREET GROUP, LLC invested $4,980,000 in shares of QGEN during the first quarter. In the first quarter, MIRABELLA FINANCIAL SERVICES LLP acquired a new stake in Qiagen N.V. valued at approximately $4,557,000. EDGESTREAM PARTNERS, L.P. acquired a new stake in QGEN for approximately $2,891,000. CIPHER CAPITAL LP purchased a new stake in QGEN valued at around $2,494,000 in the second quarter. In total, there are 654 active investors with 71.40% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $50.75 for Qiagen N.V. (NYSE: QGEN). During the past 12 months, Qiagen N.V. has had a low of $40.38 and a high of $51.30. As of last week, the company has a debt-to-equity ratio of 0.69, a current ratio of 1.80, and a quick ratio of 1.60. The fifty day moving average price for QGEN is $48.68 and a two-hundred day moving average price translates $46.58 for the stock.
The latest earnings results from Qiagen N.V. (NYSE: QGEN) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at $0.51, beating analysts’ expectations of $0.47 by 0.04. This compares to $0.57 EPS in the same period last year. The net profit margin was 20.80% and return on equity was 14.30% for QGEN. The company reported revenue of $499.63 million for the quarter, compared to $534.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.57 percent. For the current quarter, analysts expect QGEN to generate $477.07M in revenue.
Qiagen N.V.(QGEN) Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
